25 January 2024
Kromek Group
plc
("Kromek"
or the "Group")
Kromek receives £1.4m order
to deliver D3M detectors for use in EU Stockpile
Kromek Group plc (AIM: KMK), a leading
developer of radiation and bio-detection technology solutions for
the advanced imaging and CBRN detection segments, announces that it
has received an order in excess of £1.4m to supply D3M detectors
and associated networkable solutions. The revenues are expected to
be received within the current financial year.
The detectors are intended for use in the
rescEU stockpile, which is being developed by the European
Commission to help safeguard citizens from disasters and manage
emerging risks, including equipment to respond to chemical,
biological, radiological, and nuclear (CBRN) risks. The order is
fully funded by the EU, through the Directorate-General for
European Civil Protection and Humanitarian Aid
Operations.
Arnab Basu,
CEO of Kromek, said: "Amid
increasingly fraught and volatile global relations, the need for
sovereign nations to prepare for emerging risks has never been more
important.
"We are pleased to be able to
contribute positively to global efforts to safeguard citizens
against possible threats, accidental or deliberate.
"This latest order for Kromek's D3M
line of detectors is another endorsement of our world-leading
technology, which is amongst the most versatile and sensitive
available, offering real time data of any potential nuclear threat
so that decision making can be rapid and responses can be
co-ordinated effectively."
|
For
further information, please contact:
|
Kromek Group plc
|
|
|
Arnab Basu, CEO
Paul Farquhar, CFO
|
+44 (0)1740 626 060
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
|
Geoff Nash/Giles Balleny/Seamus
Fricker - Corporate Finance
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith
- Sales
|
+44 (0)20 7220 0500
|
|
|
|
|
Gracechurch Group (Financial PR)
|
|
|
Harry Chathli/Claire Norbury/Henry
Gamble
|
+44 (0)20 4582 3500
|
|
|
Kromek Group
plc
Kromek Group plc is a leading developer of radiation
detection and bio-detection technology solutions for the advanced
imaging and CBRN detection segments. Headquartered in County
Durham, UK, Kromek has manufacturing operations in the UK and US,
delivering on the vision of enhancing the quality of life through
innovative detection technology
solutions.
The advanced imaging segment comprises the medical
(including CT and SPECT), security and industrial markets. Kromek
provides its OEM customers with detector components, based on its
core cadmium zinc telluride (CZT) platform, to enable better
detection of diseases such as cancer and Alzheimer's, contamination
in industrial manufacture and explosives in aviation
settings.
In CBRN detection, the Group provides nuclear
radiation detection solutions to the global homeland defence and
security market. Kromek's compact, handheld, high-performance
radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect
critical infrastructure, events, personnel and urban environments
from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions
in the CBRN detection segment. These consist of fully automated and
autonomous systems to detect a wide range of airborne
pathogens.
Kromek is listed on AIM, a market of the London Stock
Exchange, under the trading symbol
'KMK'.